Collaborative Drug Discovery Partnership To Advance Cancer Drug Development
SRI International, an independent nonprofit research and development organization, has announced that SRI"s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed "Chemical Biology Consortium" (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel molecular and genetic cancer targets. Based on its track record of cancer drug discovery and development, SRI was chosen to lead three of the CBC"s research and development centers: Comprehensive Chemical Biology Screening, Chemical Diversity, and Specialized Applications.
Sexual Health